Alterity Therapeutics
ATHEAlterity Therapeutics is dedicated to creating disease-modifying treatments for debilitating neurodegenerative disorders, with a core focus on Parkinsonian conditions. The company's technology platform centers on metal protein attenuating compounds (MPACs) that aim to reduce the toxic accumulation of misfolded proteins in the brain. Its lead asset, ATH434, is currently in Phase 2 clinical trials, representing a potentially novel therapeutic approach for diseases with high unmet medical need. As a publicly listed entity, Alterity is advancing its pipeline through strategic clinical development to generate critical proof-of-concept data.
ATHE · Stock Price
Historical price data
AI Company Overview
Alterity Therapeutics is dedicated to creating disease-modifying treatments for debilitating neurodegenerative disorders, with a core focus on Parkinsonian conditions. The company's technology platform centers on metal protein attenuating compounds (MPACs) that aim to reduce the toxic accumulation of misfolded proteins in the brain. Its lead asset, ATH434, is currently in Phase 2 clinical trials, representing a potentially novel therapeutic approach for diseases with high unmet medical need. As a publicly listed entity, Alterity is advancing its pipeline through strategic clinical development to generate critical proof-of-concept data.
Technology Platform
Platform of orally administered, brain-penetrant metal protein attenuating compounds (MPACs) designed to inhibit the aggregation of pathological proteins like alpha-synuclein and tau by modulating metal-protein interactions in the brain.
Opportunities
Risk Factors
Competitive Landscape
Competes in MSA with Theravance Biopharma and others, and in PD with Denali, Roche/Prothena, and UCB. Key differentiation is its oral MPAC platform aiming to modify disease by reducing toxic protein aggregation, offering a potentially more accessible treatment modality compared to infused antibodies.